ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / REVB
SILO (18) SBFM (27) APVO (35) HCWB (23) ⌘ Pro Terminal →

Revelation Biosciences Inc. (REVB) — RQD Stock Rating Cockpit

$4.03 +7.47% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.08

Revelation Biosciences Inc. (REVB) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D- • RED ALERT Cap $2.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on REVB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is REVB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Revelation Biosciences Inc. (NASDAQ: REVB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $4.03 (+7.47% 1D, market cap $2.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, REVB ranks #585 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does REVB compare to SILO and SBFM in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), REVB carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SILO (Silo Pharma Inc.) holds a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $2.3M) and SBFM (Sunshine Biopharma Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -21.4%, cap $2.2M). Among the 5-stock peer group, REVB leads on earnings multiple (N/A) while SBFM leads on capital efficiency (-21.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for REVB?
▼

Per REVB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001810560), Revelation Biosciences Inc. generated $0 in revenue, -$8.9M in net income, and -$8.3M in free cash flow against $11.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.08 (+1.15%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510036
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (8)Whales (3)SEC (10)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9.9% Base Target
$43 Bull$4 Base$3 Bear
📬 FREE REVB RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for REVB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY REVB SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (28% of score)

FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 41.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
44
Grade D$5.11-26.6% Next Q
Q2 (-2Q)
41
Grade D$3.75-0.5% Next Q
Q3 (-1Q)
39
Grade E$3.73+8% Next Q
Current
36
Grade D-$4.03-8.3% Hist 90D α
Trajectory: D (44) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a REVB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While REVB currently carries a cautious 36/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.62) and Max Pain ($4.23) forces dealer call-delta covering toward $42.63.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $REVB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “REVB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 36%NO 64%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
41.630 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE3% OF RANGE
L: $3$4.03H: $41
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on REVB

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (40)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (30)

8/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like REVB
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring REVB)

  • ✓Walkthrough of REVB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
REVB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -46.69%📐 HORIZONTAL RANGE
2026-11-03O $3.75H $4.03L $3.75C $4.03VOL 22.3K
RES: $10.23SUP: $2.53SMA50: $5.62SMA200: $7.94
$9.53$7.78$6.03$4.29$2.54RES $10.23SUP $2.53$4.032026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

REVB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 REVB Butterfly Map → + Track REVB →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on REVB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for REVB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for REVB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (REVB)

Health Care Rank #585 of 1016 ⚔️ SILO vs REVB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (REVB vs. SILO, SBFM, APVO, HCWB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Revelation Biosciences Inc. (REVB) ranks #585 by composite RQD confidence (36/100, grade D-) and #991 by equity capitalization ($2.3M). Within this direct 5-issuer industry benchmark cohort, REVB leads on earnings valuation at N/A trailing P/E, while SBFM leads on capital efficiency and profitability with -21.4% ROIC and 33.8% gross margin. REVB currently leads its immediate peer cohort in composite quantitative strength at 36/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
REVB ACTIVE
Revelation Biosciences Inc.
D- 36/100 — — -35.0% +7.47% $2.3M Benchmark Subject
SILO
Silo Pharma Inc.
E 18/100 — 38.6% -35.0% -1.60% $2.3M /silo-vs-revb →
SBFM
Sunshine Biopharma Inc.
E 27/100 — 33.8% -21.4% -12.01% $2.2M /sbfm-vs-revb →
APVO
Aptevo Therapeutics Inc.
D- 35/100 — — -35.0% -1.47% $2.4M /apvo-vs-revb →
HCWB
HCW Biologics Inc.
E 23/100 — 20.0% -35.0% -6.78% $2.5M /hcwb-vs-revb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001810560

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Revelation Biosciences Inc. (REVB) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$8.9M, operating cash flow of -$8.3M, and free cash flow of -$8.3M (+54.9% YoY). On the balance sheet, REVB closed FY2025 with $11.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $0 -$8.9M -$8.3M -$8.3M $11.6M —
FY2024 (FY) 2024-12-31 $0 -$15.0M -$18.3M -$18.3M $6.6M —
FY2023 (FY) 2023-12-31 $0 -$120.3K -$7.3M -$7.3M — —

3. REVB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is REVB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Revelation Biosciences Inc. (NASDAQ: REVB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $4.03 (+7.47% 1D, market cap $2.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, REVB ranks #585 in composite RQD confidence.

How does REVB compare to SILO and SBFM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), REVB carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SILO (Silo Pharma Inc.) holds a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $2.3M) and SBFM (Sunshine Biopharma Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -21.4%, cap $2.2M). Among the 5-stock peer group, REVB leads on earnings multiple (N/A) while SBFM leads on capital efficiency (-21.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for REVB?

Per REVB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001810560), Revelation Biosciences Inc. generated $0 in revenue, -$8.9M in net income, and -$8.3M in free cash flow against $11.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is REVB trading relative to its 50-day, 200-day, and 52-week technical levels?

REVB last traded at $4.03 (+7.47% on volume of 22,253 shares), positioning the stock -28.29% below its 50-day simple moving average ($5.62) and -49.24% below its 200-day simple moving average ($7.94). Across its 52-week range of $3.04 to $40.60, REVB sits at the 2.6% percentile with a 14-day RSI of 41.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.53 to $4.53).

REVB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell REVB stock right now?

Revelation Biosciences Inc. (REVB) currently earns a Roarable Rating of D- (Sell — SELL) with 36/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is REVB's 12-month price target and RQD AI Jury consensus?

REVB's 12-month base price target is $3.63 (range $2.83 to $42.63), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: REVB RQD Cockpit REVB 12M Forecast REVB Earnings & Move REVB Dividends & DRIP REVB Insiders & 13F REVB Whale Options REVB Profit Sankey REVB News & Why
ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

REVB — Revelation Biosciences Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:54:43Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, REVB scores 36 out of 100, earning a D- grade and the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars: Fundamental Cash Engine scores 8/20 (ROIC of -35% and FCF yield of 0%), Whale 13F Flow scores 3/20 (institutional accumulation and options positioning), Insider Conviction scores 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit scores 10/20 (Beta of 1.0 and sector sensitivity), and Forensic Balance Sheet scores 10/20 (Altman Z of 2.5, Piotroski F of 3/9, Debt/Equity of 0.5).

For a prospective investor, the rating reflects a company that is not generating operating cash flow relative to its reported losses, with institutional and insider flow scoring weakly. The forensic pillar is the most balanced of the five, with the Altman Z-Score and Debt/Equity ratio sitting in a range the rating does not classify as distressed, while the Piotroski F-Score of 3/9 indicates weak fundamental quality signals. Valuation tradeoffs are difficult to assess because P/E, Forward P/E, EV/EBITDA, and EPS are not available in source data; with negative ROIC and zero FCF yield, the source data offers no earnings-based valuation anchor. Any upside case would depend on factors outside the scored pillars, and the source data does not establish one.

Open Questions

  • What are the company's revenue sources, given reported revenue of $0.0M across all periods?
  • What is the cash runway implied by $10.7M of FY 2025 cash against $-8.3M of FY 2025 free cash flow?
  • What is the financial and share-count impact of the 1-for-7 reverse stock split effective October 20, 2026?
  • What are the debt obligations, given that debt is N/A for all reported periods while Debt/Equity is 0.5?
  • What insider and institutional transactions underlie the RQD insider and whale pillar scores?

REVB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Revelation Biosciences Inc. (REVB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to REVB Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

REVB Bull vs. Bear Conversation Board — What's Your Call at $4.03?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON REVB 🐻 67% BEARISH CONVICTION
1. Pick Your Side on REVB:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $3.30 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is REVB (D- • RQD 36/100) a Buy at $3.75?

Welcome to the REVB (Revelation Biosciences Inc.) Roar Pit. Current RQD Composite is 36/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.93 (-21.9%)
Spot @ $3.75

Pump the brakes on REVB — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on REVB, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Revelation Biosciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $4.31 (+14.9%)
Spot @ $3.75

REVB cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on REVB, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.75 (52-wk range $3.04 - $40.60), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%